Member Info for BuenaVista

It would mean contracting the work out, as now, as it will be for nearly all aspects of taking this to market.

Phrmaceutical grade AVA6000, GMP-accredited formulating facility, stability testing. This would surey be started for late clinical trial phases to obviate any unnecessary delays, including finding mass production slots.

Ooh look! Another deadline being set!

clarification, not classification

From the RNS:

"On the basis of the very favourable safety profile of AVA6000 in the study to date, the Safety Data Monitoring Committee (SDMC) has recommended continuation to higher dose cohorts with the aim of identifying a maximum tolerated dose (MTD) necessary to inform the dosing levels for the phase 1b and future studies."

If it were solely up to the SDMC, they would have selected a new dose level when taking the decision to continue Phase 1a. As it was, they "recommended" continuation. I'm sure they'll have decided what options they want for future dosing, e.g. increase by 60 but by 40 is OK. I can only see the delay being because some authority needs to be consulted for approval. For example the Ethics Committee need time to go through the data and no doubt will want classification and more details about certain aspects. That will all take time and is beyond Avacta's control. Or it could possibly be the regulatory authority, the MHRA, even the FDA if doxorubicin-breaking changes are being asked for in studies in the US, need to be consulted or to give permission.

That 5140 structure is just embarrassing.

Would love an RNS saying the board had received and rejected an unsolicited offer for the company. That would really fire the starting gun.

I know it's a conplete waste of time so I voted YES!!!!! Sorry NO, absolutely not. A hypothetical 800p? Pfft!

I'd not seen that before. Thanks.

Other priorities is another possibility. The leads seem to becoming from er... Leeds.

Da Dum... Tish!

I'll get my coat

All is not lost Cheesey as the remaining patent life for Affimers is long enough to discover commercially exploitable uses that will have their own 20 year patent protection. Also, pre|CISION seems destined to account for most of the SP for the foreseeable. However, if someone can reason why Affimers are set left on the starting block, I'm all ears.

I can't help feeling that, for all their projected promise, Affimers are being underexploited commercially. Today Aptamer announced 2 agreements for their Optimers "initially worth over £500,000, subject to the successful progression of Optimer development, with the potential for downstream milestone and royalty/licensing payments". These were described as 'substantial' but that is relative as the Aptamer MCap is only £27m or so. Despite that small MCap, Aptamer have many more partners than Avacta for this technology, including AstraZeneca, Cancer Research UK and even Takeda. And Deepverge of course.
https://aptamergroup.com/portfolio/

If Affimers are so specific for this and that target, where are the licence agreements? If baffles me.

Terry's over at KOD getting spiked

Get this:

Phase II studies

Doctors use the information gathered in a Phase I study to help decide:
- the dose of treatment
- the frequency of treatment
- the particular cancers which may respond best to the treatment.

Several Phase II trials will be carried out on different cancers so that doctors can find out how active a particular drug is. Only about 20 to 30 patients with each cancer are needed to take part in this early work for each tumour type. They will be watched very carefully for the effects and side effects of treatment using regular check-ups, blood tests, x-rays or scans. If the drug doesn’t work, no more trials will be carried out. However, if a significant number of responses are seen, the doctors will design a Phase III study.

Phase III studies

A Phase III study will try to compare a new treatment with the best treatment currently available and the following are monitored:
- the effect of the treatment on the cancer
- how long the effects last
- the side effects of the treatment
- any possible longer-term problems which could develop.

If the differences between the new treatment and the existing treatment are small, hundreds of patients may need to take part before one is identified as better than the other. Studies may take place in several different hospitals at the same time, including hospitals in other countries.

Phase III trials are usually randomised and may include a double-blind procedure. Find out more about organising clinical trials.
https://www.royalmarsden.nhs.uk/about-royal-marsden/our-research/clinical-trials/what-types-clinical-trial-are-there

-----------------------

How could a Phase III study possibly be organised when the standard treatment (doxorubicin or any of the other anthracyclines) causes obvious side effects whilst AVA6000 doesn't and its efficacy will have already been proven in Phase II? A complete nonsense given that the efficacy of straight doxorubicin is so well known; no need to do a live comparison study, just look at the data in doxorubicin trial reports!

£3 or £30?

Systemzero needs to know because he'll be selling at £3.

How did you arrive at £10 per share?
Please show your workings.
;0)

Did you ask for 100 word paragraphs PL?

I'll lay a place for ChatGPT at the next dinner party. He can keep the guests entertained whilst the burnt joint is being recovered.

Geopolitical consequences of Russia's Special Military Embarrassment in Ukraine anyone?

Sorry, I can't see that. I have you on filter.

What do the charts say the shareprice will move to when the dose escalation RNS is released?

Looking for contracts?

Looking for contracts?